# Treatment of Mild-moderate Clostridium Difficile Infection (CDI)

> **NCT04121169** · PHASE2 · UNKNOWN · sponsor: **ImmuniMed Inc.** · enrollment: 60 (estimated)

## Conditions studied

- Clostridium Difficile Infection (CDI)

## Interventions

- **DRUG:** IM-01

## Key facts

- **NCT ID:** NCT04121169
- **Lead sponsor:** ImmuniMed Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-10-04
- **Primary completion:** 2023-12-30
- **Final completion:** 2024-03-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2022-12-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04121169

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04121169, "Treatment of Mild-moderate Clostridium Difficile Infection (CDI)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04121169. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*